Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04662801
Other study ID # 2000029491
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date August 5, 2021
Est. completion date September 13, 2022

Study information

Verified date October 2023
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will examine behavioral and pharmacologic (Naltrexone+Bupropion) treatments for weight regain after bariatric surgery.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date September 13, 2022
Est. primary completion date September 13, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Be in the age range =18 years of age and =70 years of age - Have a BMI =30 (or BMI =27 with a medical comorbidity) and =50 kg/m2 - Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy - Experiencing weight regain after bariatric surgery - Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators (physical examination, laboratory studies). - Read, comprehend, and write English at a sufficient level to complete study-related materials. - Provide a signed and dated written informed consent prior to study participation. - Be available for participation in the study for up to 3 months. Exclusion Criteria: - Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold). - Has a history of anorexia nervosa or history of bulimia nervosa. - Is currently taking a medication that is a contraindication to NB medication (e.g., MAOI, opiates). - Is currently using other medications for weight loss. - Has a history of allergy or sensitivity to bupropion or naltrexone. - Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression) - Has untreated hypertension with a seated systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg, or heart rate > 100 beats/minute. - Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke. - Has current uncontrolled hypertension. - Has current uncontrolled Type I or Type II diabetes mellitus. - Has untreated hypothyroidism with a TSH > 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit. - Has gallbladder disease. - Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder. - Has a recent history of drug or alcohol dependence (since having bariatric surgery). - Is currently in active treatment for eating or weight loss. - Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device. - Is breast-feeding or is pregnant or is not using a reliable form of birth control. - Reports active suicidal or homicidal ideation.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Behavioral Weight Loss (BWL)
All participants will receive twelve weeks of BWL treatment.
Early Responder: BWL continued
Participants categorized as experiencing early weight loss at the end of the first month of treatment will continue with BWL for the remainder of treatment.
Combination Product:
Early Non-responder: BWL continued with medication added
Participants categorized as not experiencing early weight loss at the end of the first month of treatment will continue BWL plus a weight loss medication (Naltrexone Bupropion) for the remainder of treatment.

Locations

Country Name City State
United States Yale University New Haven Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Yale University American Psychological Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Body Mass Index BMI is calculated using measured height and weight- kg/m2. Post-treatment (3 months)
Secondary Eating Disorder Psychopathology Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology). Post-treatment (3 months)
Secondary Food Craving Food craving will be assessed by the Food Craving Inventory (FCI). FCI scores range from 1-5, with higher scores indicative of greater craving. Post-treatment (3 months)
Secondary Depressive Symptoms Depressive symptoms will be assessed by the Patient Health Questionnaire-9. The range is 0-27, which higher scores indicative of greater depressive symptomatology Post-treatment (3 months)
See also
  Status Clinical Trial Phase
Completed NCT05822167 - Effect of Food Temperature and Diet Composition on Satiety, Satiety Hormones, Chewing Time and Neuronal Activity N/A